ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Insulin Glargine

Also written as “insulin glargine”, “Insulin glargine” and “INSULIN GLARGINE”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Diabetes Mellitus · Hyperglycemia · Glucose Intolerance, led by 9 companies.

Drug pageInsulin Glargine: every studyMany companies study it; this page follows only the 184 they lead. All 294 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 9, 2005184 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi1241 open or runningphase 4since Sep 9, 2005Sep 30, 2002none ahead
Novo Nordiskits history only280 open or runningphase 4since Sep 12, 2005Oct 29, 2004none ahead
Eli Lillyits history only250 open or runningphase 4since Sep 12, 2005Sep 12, 2005none ahead
Diabetes Care Centerits history only20 open or runningno phasesince Apr 3, 2007Apr 3, 2007none ahead
Biodelits history only10 open or runningphase 2since Oct 21, 2009Oct 21, 2009none ahead
Geropharmits history only10 open or runningno phasesince Sep 23, 2019Sep 23, 2019none ahead
ikfe-CROits history only10 open or runningphase 4since Dec 5, 2011Dec 5, 2011none ahead
Profil Institut für Stoffwechselforschungits history only10 open or runningphase 1since Sep 3, 2009Sep 3, 2009none ahead
Wockhardtits history only10 open or runningphase 1since May 12, 2011May 12, 2011none ahead

Also a collaborator on its studies: PPD DEVELOPMENT, LP, Alkermes and Boehringer Ingelheim.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sanofi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 45 studies since Jun 16, 2010.

  1. Aug 14, 2017Phase 4 study in Diabetes Mellitus, Type 1NCT03260868 · 15 enrolled · United States, Canada
  2. Nov 21, 2017Phase 4 study in Diabetes Mellitus, Type 2NCT03359837 · 384 enrolled · China
  3. Jan 15, 2018Phase 4 study in Diabetes Mellitus, Type 1NCT03406000 · 170 enrolled · Brazil
  4. Feb 9, 2018Phase 3 study in Diabetes Mellitus, Type 2NCT03434119 · 241 enrolled · United States
  5. May 7, 2018Phase 3 study in Diabetes Mellitus, Type 2NCT03529123 · 247 enrolled · India
  6. Nov 29, 2018Phase 4 study in Diabetes Mellitus, Type 2NCT03760991 · 372 enrolled · Argentina, Colombia, Egypt and more
  7. Dec 5, 2018Phase 3 study in Diabetes Mellitus, Type 2NCT03767543 · 265 enrolled · Canada
  8. Jan 7, 20192 phase 3 studies in Diabetes Mellitus, Type 2NCT03798080, NCT03798054
  9. Aug 29, 2019Phase 4 study in Diabetes Mellitus, Type 1NCT04075513 · 343 enrolled · United States, Brazil, Germany and more
  10. Jul 19, 2021Phase 4 study in Diabetes Mellitus, Type 2NCT04980027 · 228 enrolled · India
  11. Oct 29, 2021Phase 4 study in Diabetes Mellitus, Type 2NCT05114590 · 124 enrolled · United States
  12. Jun 7, 2022Phase 3 study in Diabetes Mellitus, Type 2NCT05413369 · 582 enrolled · China
  13. Sep 7, 2022Phase 4 study in Diabetes Mellitus, Type 2NCT05552859 · 62 enrolled · United States, Czechia, Hungary and more
  14. Oct 31, 2024Phase 4 study in Diabetes Mellitus, Type 2NCT06671587 · 678 planned · China

TargetBeta

INSR →read by rule
“Insulin receptor agonist”ChEMBL 37, by rule

Other programs on INSR

ProgramCompanyFurthest phaseStudies
Insulin AspartruleNovo Nordiskphase 4146
insulin degludecruleNovo Nordiskphase 4108
InsulinrulePfizerphase 450
insulin glulisineruleSanofiphase 443
insulin icodecruleNovo Nordiskphase 430
linsitinibruleAstellas Pharmaphase 313
LY3938577Eli Lillyphase 23

Studies

The newest 60 of 124 Sanofi leads. Each opens its study page. Every study on its drug page →

StudyPhaseStatusPrimary completionSize
NCT06671587Diabetes Mellitus, Type 2 · China4RecruitingSep 18, 2026678
NCT05552859Diabetes Mellitus, Type 2 · United States, Czechia, Hungary and more4TerminatedJul 28, 202362
NCT05413369Diabetes Mellitus, Type 2 · China3CompletedOct 20, 2023582
NCT05114590Diabetes Mellitus, Type 2 · United States4CompletedMar 28, 2023124
NCT04980027Diabetes Mellitus, Type 2 · India4CompletedDec 23, 2022228
NCT04075513Diabetes Mellitus, Type 1 · United States, Brazil, Germany and more4CompletedSep 16, 2021343
NCT03798080Diabetes Mellitus, Type 2 · China3CompletedDec 1, 2020426
NCT03798054Diabetes Mellitus, Type 2 · China, Korea, Republic of, Malaysia and more3CompletedMar 1, 2021878
NCT03767543Diabetes Mellitus, Type 2 · Canada3CompletedOct 23, 2020265
NCT03760991Diabetes Mellitus, Type 2 · Argentina, Colombia, Egypt and more4CompletedSep 23, 2020372
NCT03529123Diabetes Mellitus, Type 2 · India3CompletedNov 25, 2019247
NCT03434119Diabetes Mellitus, Type 2 · United States3TerminatedJan 7, 2019241
NCT03406000Diabetes Mellitus, Type 1 · Brazil4CompletedFeb 4, 2019170
NCT03359837Diabetes Mellitus, Type 2 · China4CompletedJun 29, 2020384
NCT03260868Diabetes Mellitus, Type 1 · United States, Canada4TerminatedNov 22, 201815
NCT02967237Diabetes Mellitus, Type 2 · France4CompletedJul 24, 2017136
NCT02967224Diabetes Mellitus, Type 2 · Brazil, France, Germany and more4CompletedOct 16, 2017705
NCT02967211Diabetes Mellitus, Type 2 · Brazil, Finland, France and more4CompletedOct 20, 2017609
NCT02855684Diabetes Mellitus, Type 2 · China, Korea, Republic of, Taiwan3CompletedAug 6, 2018604
NCT02836704Diabetes Mellitus, Type 2 · China4CompletedApr 26, 2018892
NCT02787551Diabetes Mellitus, Type 2 · United States, Canada, Estonia and more3CompletedMay 25, 2018514
NCT02752828Diabetes Mellitus, Type 2 · Japan3CompletedMar 12, 2018521
NCT02752412Diabetes Mellitus, Type 2 · Japan3CompletedOct 4, 2018513
NCT02749890Diabetes Mellitus, Type 2 · Japan3CompletedMay 2018321
NCT02738151Diabetes Mellitus, Type 2 · United States, Bulgaria, Croatia and more4CompletedAug 15, 2017929
NCT02735044Diabetes Mellitus, Type 1 · United States, Argentina, Brazil and more3CompletedMay 31, 2018463
NCT02713477Diabetes Mellitus, Type 2 · Japan1CompletedJun 201620
NCT02688933Diabetes Mellitus, Type 1 · United States, Puerto Rico4CompletedJun 19, 2017638
NCT02606357Diabetes Mellitus, Type 2 · Jordan4CompletedNov 27, 2017242
NCT02545842Diabetes Mellitus, Type 2 · China4CompletedApr 20, 2018947
NCT02451137Diabetes Mellitus, Type 2 · United States, Canada4CompletedMar 2, 20183,304
NCT02401243Diabetes Mellitus, Type 2 · Canada3CompletedFeb 2016253
NCT02320721Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more3CompletedMay 20161,014
NCT02227212Diabetes Mellitus, Type 2 · Germany3CompletedNov 201440
NCT02201199Diabetes Mellitus, Type 1 · Germany1CompletedNov 201436
NCT02058160Diabetes Mellitus, Type 2 · United States, Australia, Canada and more3CompletedJul 2015736
NCT02058147Diabetes Mellitus, Type 2 · United States, Australia, Belgium and more3CompletedJun 20151,170
NCT02027753Diabetes Mellitus, Type 2 · Korea, Republic of4CompletedApr 2015109
NCT01838083Type1 Diabetes · Germany1CompletedAug 201350
NCT01689142Diabetes Mellitus, Type 2 · Japan3CompletedNov 2013240
NCT01689129Diabetes Mellitus, Type 1 · Japan3CompletedOct 2013243
NCT01683266Diabetes Mellitus, Type 1 · United States, Canada, Czech Republic and more3CompletedSep 2013549
NCT01676233Diabetes Mellitus, Type 1 · Japan1CompletedAug 201320
NCT01676220Diabetes Mellitus, Type 2 · United States, Bulgaria, Canada and more3CompletedSep 2013878
NCT01658579Diabetes Mellitus, Type 1 · United States2CompletedMay 201359
NCT01499095Diabetes Mellitus, Type 2 · United States, Canada, Chile and more3CompletedApr 2013811
NCT01499082Diabetes Mellitus, Type 2 · United States, Canada, Czechia and more3CompletedJan 2013807
NCT01493115Diabetes Mellitus, Type 1 · Japan1CompletedApr 201218
NCT01476475Diabetes Mellitus, Type 2 · United States, Chile, Czech Republic and more2CompletedDec 2012323
NCT01349855Diabetes Mellitus, Type 1 · Germany1CompletedMay 201130
NCT01336751Diabetes Mellitus, Type 2 · United States3CompletedDec 2002212
NCT01234597Diabetes Mellitus, Type 2 · Israel4CompletedApr 2015219
NCT01226043Diabetes Mellitus, Type 2 · United States4CompletedMay 2012405
NCT01223131Diabetes Mellitus, Type 1 · China3CompletedMar 2014162
NCT01212913Diabetes Mellitus, Type 2 · Korea, Republic of4CompletedMay 2012161
NCT01204593Diabetes Mellitus, Type 1 · Algeria, Argentina, Brazil and more4CompletedJan 2013206
NCT01202474Diabetes Mellitus, Type 1 · Russian Federation4CompletedOct 2012100
NCT01195454Diabetes Mellitus, Type 1 · Germany1CompletedNov 201024
NCT01169818Diabetes Mellitus, Type 2 · China, India, Japan and more4CompletedJun 2012555
NCT01146678Diabetes Mellitus, Type 1 · Germany1CompletedSep 201022

How it is read

Names in the registry

  • “insulin glargine”, 38 entries
  • “Insulin Glargine”, 27 entries
  • “Insulin glargine”, 20 entries
  • “INSULIN GLARGINE”, 15 entries
  • “LY2963016”, 11 entries

Codes read as this program: HOE901.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.